141 related articles for article (PubMed ID: 19409691)
1. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach.
Gardiner RA; Sweeney C; Tilley WD
Eur Urol; 2009 Aug; 56(2):245-6. PubMed ID: 19409691
[No Abstract] [Full Text] [Related]
2. Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.
Drewa T; Chlosta P
Eur Urol; 2010 Feb; 57(2):e18-9; author reply e20. PubMed ID: 19853990
[No Abstract] [Full Text] [Related]
3. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Guess B; Scholz M
J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
[No Abstract] [Full Text] [Related]
4. Malignant disease of the prostate gland.
Marsh M
Nurs Stand; 1992 May 27-Jun 2; 6(36):28-31. PubMed ID: 1622801
[TBL] [Abstract][Full Text] [Related]
5. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
Morris MJ; Huang D; Kelly WK; Slovin SF; Stephenson RD; Eicher C; Delacruz A; Curley T; Schwartz LH; Scher HI
Eur Urol; 2009 Aug; 56(2):237-44. PubMed ID: 19375217
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
Smith JA
Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
[No Abstract] [Full Text] [Related]
8. [Prostatic hormone-resistant cancer: present-day drug prophylaxis and treatment].
Sivkov AV; Alfimov AE; Imamov OE
Urologiia; 1999; (5):33-9. PubMed ID: 11150155
[No Abstract] [Full Text] [Related]
9. Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
Heidenreich A
Eur Urol; 2008 Oct; 54(4):726-7. PubMed ID: 18524468
[No Abstract] [Full Text] [Related]
10. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
Sartor O
J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
[No Abstract] [Full Text] [Related]
11. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
Berdah JF
Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
[No Abstract] [Full Text] [Related]
12. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
van Poppel H; Nilsson S
Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Tombal B
Eur Urol; 2009 Feb; 55(2):321. PubMed ID: 18838209
[No Abstract] [Full Text] [Related]
14. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel P
BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
[No Abstract] [Full Text] [Related]
15. Non-suppression of testosterone in patients with a rising prostate-specific antigen level receiving luteinising hormone-releasing hormone analogues for metastatic prostate cancer.
Koupparis AJ; Tyrrell C
Clin Oncol (R Coll Radiol); 2006 Sep; 18(7):571-2. PubMed ID: 16972347
[No Abstract] [Full Text] [Related]
16. Guest editorial: Bilateral orchidectomy should not be considered an obsolete alternative for metastatic cancer of the prostate.
Morales A
Can J Urol; 2012 Oct; 19(5):6414-6. PubMed ID: 23040618
[No Abstract] [Full Text] [Related]
17. [Combination of P32 and testosterone in the treatment of pain due to osseous metastasis of prostate neoplasms].
García de la Peña E; Sánchez Martín JA; Linazasoro JM; Cifuentes Delatte L
Rev Clin Esp; 1974 Sep; 134(6):527-34. PubMed ID: 4141512
[No Abstract] [Full Text] [Related]
18. The Japanese experience: use of transrectal ultrasound in the evaluation of tumor response to various treatment modalities.
Watanabe H
Prog Clin Biol Res; 1987; 237():195-208. PubMed ID: 3120200
[No Abstract] [Full Text] [Related]
19. Emerging therapies in castrate-resistant prostate cancer.
Lassi K; Dawson NA
Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
[TBL] [Abstract][Full Text] [Related]
20. [The LH-RH analogs. Drug treatment of prostate cancer].
Gerson C
Soins; 1995 Nov; (600):61-2. PubMed ID: 8715119
[No Abstract] [Full Text] [Related]
[Next] [New Search]
